Overview

Phase I Study of DS-2741a in Healthy Volunteers and Participants With Atopic Dermatitis

Status:
Terminated
Trial end date:
2020-12-18
Target enrollment:
Participant gender:
Summary
This is a phase 1, single-center, first-in-human study to assess the safety, pharmacokinetics and pharmacodynamics of DS-2741a after subcutaneous injection in healthy Japanese male volunteers and Japanese participants with moderate to severe atopic dermatitis.
Phase:
Phase 1
Details
Lead Sponsor:
Daiichi Sankyo Co., Ltd.